We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Gene Expression Profiling of Mucinous Ovarian Tumors Identifies Prognosis Markers

By LabMedica International staff writers
Posted on 18 Oct 2022
Print article
Image: The BenchMark ULTRA system is Roche Tissue Diagnostics’ most innovative, fully-automated immunohistochemistry and in situ hybridization slide staining system (Photo courtesy of Roche Group)
Image: The BenchMark ULTRA system is Roche Tissue Diagnostics’ most innovative, fully-automated immunohistochemistry and in situ hybridization slide staining system (Photo courtesy of Roche Group)

Advanced stage mucinous ovarian tumors have poor chemotherapy response and prognosis and lack biomarkers to aid Stage I adjuvant treatment. Differentiating primary mucinous ovarian carcinoma (MOC) from gastrointestinal (GI) metastases to the ovary is also challenging due to phenotypic similarities.

MOC is a rare histological type that is less well characterized compared to more common ovarian cancer histotypes. A clinical problem frequently encountered in patients diagnosed with advanced stage MOC is the uncertainty as to whether the primary cancer is ovarian or metastatic from other sites. Metastases typically originate from the gastrointestinal (GI) tract, and the primary tumor may not be evident at surgery or on imaging.

A large international team of Medical Scientists led by the group at The University of New South Wales (Sydney, Australia) analyzed clinicopathological and gene expression data were to identify prognostic and diagnostic features. Discovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was performed through the Ovarian Tumor Tissue Analysis consortium and GI cancer biobanks comprising 604 patients: 333 with MOC, 151 with mucinous borderline ovarian tumors (MBOT), 65 with upper G, and 55 with lower GI tumors.

RNA samples from a total of 634 patients were eligible for the NCounter PlexSet assay (Nanostring, Seattle, WA, USA) extracted from either 403 formalin-fixed, paraffin embedded (FFPE) whole sections, 191 FFPE cores, or 40 fresh-frozen sections. A second sample was analyzed in a subset of 33 patients: either multiple blocks from the same tumor or multiple tumor tissue sites. The team performed ERBB2/HER2 immunochemistry (IHC) using anti-HER2/neu (4B5), and Silver-enhanced in situ hybridization (SISH) using HER2/Ch17 Dual ISH DNA Probe Cocktail, (Roche Diagnostics, Indianapolis, IN, USA). Staining was performed on the Ventana Benchmark ULTRA Platform (Roche Group, Tucson, AZ, USA) on 4 µm tissue microarray sections for a subset of cases from one study.

The investigators reported that infiltrative pattern of invasion was associated with decreased overall survival (OS) within 2-years from diagnosis, compared with expansile pattern in Stage I MOC (hazard ratio HR 2.77). Increased expression of THBS2 and TAGLN were associated with shorter OS in MOC patients, (HR 1.25) and (1.21) respectively. ERBB2 (HER2)-amplification or high mRNA expression was evident in 64/243 (26%) of MOCs, but only 8/243 (3%) were also infiltrative (4/39, 10%) or Stage III/IV (4/31, 13%).

The authors concluded that an infiltrative growth pattern infers poor prognosis within 2-years from diagnosis and may help select Stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confer an adverse prognosis and is upregulated in the infiltrative subtype which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies. The study was published on October 12, 2022 in the journal Clinical Cancer Research.

Related Links:
The University of New South Wales
Nanostring 
Roche Diagnostics 
Roche Group

Platinum Supplier
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
BCID Panels
ePlex Blood Culture Identification Panels
New
Fecal Calprotectin Testing Reagent
OC-FCa Reagent
New
Pipetting Workstation
Microlab NIMBUS

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)

DBS-Based Assay Effective in Hepatitis C Diagnosis and Treatment for At Risk Populations

In a bid to eliminate viral hepatitis as a public health threat by 2030, the World Health Organization (WHO) has put forth a proposed strategy. To this end, researchers at the Germans Trias i Pujol Research... Read more

Pathology

view channel
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: The global antimicrobial resistance diagnostics market size is expected to reach USD 5.7 billion by 2028 (Photo courtesy of Pexels)

Global Antimicrobial Resistance Diagnostics Market Driven by Increasing Hospital-Acquired Infections

Antimicrobial drugs are intended to counteract the harmful effects of microbes and promote a healthy life. However, their excessive use can result in the development of resistance, commonly referred to... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.